Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal Holdings's Other Operating Expense for the
three
months ended in Mar. 2026 was 円46,030 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円184,225 Mil.
Medipal Holdings's quarterly Other Operating Expense
declined
from Sep. 2025 (円48,218 Mil) to Dec. 2025 (円44,275 Mil) but then
increased
from Dec. 2025 (円44,275 Mil) to Mar. 2026 (円46,030 Mil).
Medipal Holdings's annual Other Operating Expense
declined
from Mar. 2024 (円178,846 Mil) to Mar. 2025 (円176,552 Mil) but then
increased
from Mar. 2025 (円176,552 Mil) to Mar. 2026 (円182,951 Mil).
Medipal Holdings Other Operating Expense Related Terms
Medipal Holdings Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円184,225 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of 円184,225 Mil mean?
Medipal Holdings (TSE:7459) has a Other Operating Expense of 円184,225 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Medipal Holdings and its competitors.
Is Medipal Holdings' Other Operating Expense too high?
Medipal Holdings' current Other Operating Expense is 円184,225 Mil. Overall, Medipal Holdings has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Other Operating Expense compare to MCK and COR?
Medipal Holdings' Other Operating Expense of 円184,225 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Distribution company?
A good Other Operating Expense depends on the Medical Distribution industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Medipal Holdings and its competitors. Medipal Holdings's current Other Operating Expense is 円184,225 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (TSE:7459) is currently considered Fairly Valued. The stock's GF Value™ is 円2,738.75, compared to a current price of 円2,816.50 — trading 2.8% above its estimated fair value. The current Other Operating Expense is 円184,225 Mil. Medipal Holdings' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Medipal Holdings (TSE:7459), the current Other Operating Expense is 円184,225 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (TSE:7459) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of 円2,816.50 is trading 2.8% above its estimated GF Value™ of 円2,738.75.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for TSE:7459:
Other Operating Expense: 円184,225 Mil
GF Value™: 円2,738.75 vs. price of 円2,816.50 (2.8% above fair value)
No single metric tells the full story. See the TSE:7459 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
84GF Score
Get the complete analysis for TSE:7459
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7459 has been successfully added to your 
